Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Brimonidin (amtlicher ATC-Code: S01EC24)
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...
The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Oct 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2027
- Conclusion of non-exclusive pharmaceutical rebate agreements under § 130a(8) SGB V for Brinzolamid/Brimonidin.
- Open-House model: any interested company may join during the participation period if it meets and accepts the conditions.
Show full summary
This is an Open-House pharmaceutical supply arrangement for the active substance Brinzolamid/Brimonidin (ATC S01EC24) with AOK PLUS. It is non-exclusive, open to all interested pharmaceutical companies that meet the stated participation conditions, with no individual negotiations and no guaranteed minimum purchase volume. Participation is handled electronically via DTVP, but submission is not via the bidder tool; the participation documents must be obtained from the project room after access approval. The notice is highly document-dependent, but the extracted procurement documents are not available beyond the XML notice text, so some submission details remain incomplete.
Risks
The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...
The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
Eligibility
- The bidder must declare no mandatory or discretionary exclusion grounds using the provided self-declaration form.
Administrative
- A declaration regarding Russia sanctions compliance is required using the specified form.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Open-House pharmaceutical supply agreement for Brinzolamid/Brimonidin
Non-exclusive supply/framework-style Open-House agreement for pharmaceutical products containing Brinzolamid/Brimonidin (ATC S01EC24). Scope is the conclusion of rebate agreements with all eligible pharmaceutical companies. Place of performance is Dresden, Germany, with performance also linked to Saxony and Thuringia as stated in the notice text.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Brimonidin (amtlicher ATC-Code: S01EC24)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 24 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 551011-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
46 / 100
Complexity
58 / 100
Risk factors
The notice says participation documents are obtained via the DTVP project room after access approval, and that some por...
The contracting authority states that demand is unknown and minimum purchase quantities are not guaranteed.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications